Skip to content
Screener

Jazz Pharmaceuticals JAZZ Change in estimate, amount

Change in estimate, amount at other companies

Southern First Bancshares logo
Southern First BancsharesSFST
$652K
Monro, Inc. logo
Monro, Inc.MNRO
-$135.75K
Ashland logo
AshlandASH
-$22M+53.2%
FMC Corporation logo
FMC CorporationFMC
$35.73M+23.2%
LyondellBasell Industries N.V. logo
LyondellBasell Industries N.V.LYB
$11.25M+55.2%
Revvity logo
RevvityRVTY
$13.98M+220%

Other financials

Income statement

See full
Revenue$1.1B+19.1%
Operating income$336.6M+702%
Net income$293.1M+417%
EPS (diluted)$4.43+391%

Balance sheet

See full
Cash & equivalents$667.5M-64.1%
Total debt$5.4B-0.1%
Total equity$4.5B+8.6%
Total assets$11.9B+2.8%

Cash flow

See full
Operating cash flow$408.2M-5.0%
CapEx$19.7M+41.7%
Free cash flow$388.5M-6.6%

Valuation

See full
Market cap$16.65B+148%
Enterprise value$21.39B+95.4%
P/S3.8×+2.1×

Profitability

See full
Operating margin-11.9%-28.1pp
Net margin-8.9%-20.5pp
FCF margin28.6%-8.6pp

Returns & leverage

See full
Return on equity-9.1%-21.2pp
Debt / equity1.2×-0.1×
Current ratio-1.3×

Where this comes from

Reported directly by Jazz Pharmaceuticals in its filing.

Tagged under the XBRL concept jazz:EffectiveIncomeTaxRateReconciliationChangeInEstimateAmount.

The source filing: Jazz Pharmaceuticals’s 10-K, filed February 24, 2026.

Filed
Feb 24, 2026, 4:10 PM EST
Fiscal year
FY2028
Accession
0001232524-26-000013
Line itemYear Ended December 31, 2024Year Ended December 31, 2023
Income tax expense at the statutory income tax rate$58,794$37,241
Change in valuation allowance201,99675,081
Deduction on subsidiary equity(180,460)(153,655)
Change in estimates(1)(106,007)(5,472)
Patent box incentive benefit(2)(65,413)(13,862)
Research and other tax credits(65,255)(49,900)
Foreign derived intangible income benefit(39,470)(42,400)
Foreign income tax rate differential38,346(7,763)

Item 16. Form 10-K Summary

FAQ

What is Jazz Pharmaceuticals's change in estimate, amount?
Jazz Pharmaceuticals (JAZZ) reported change in estimate, amount of -$26.5M in Q4 2024.
How has Jazz Pharmaceuticals's change in estimate, amount changed year-over-year?
Jazz Pharmaceuticals's change in estimate, amount decreased by 1837.3% year-over-year, from -$1.37M to -$26.5M.
What is the long-term trend for Jazz Pharmaceuticals's change in estimate, amount?
Over 3 years (2021 to 2024), Jazz Pharmaceuticals's change in estimate, amount has grown at a 241.9% compound annual growth rate (CAGR), from -$2.65M to -$106.01M.
What does change in estimate, amount mean?
Reflects the impact of revisions to accounting estimates regarding tax positions or deferred tax assets. These changes occur when management updates assumptions about future tax outcomes based on new information or operational shifts.

Ask your AI about Jazz Pharmaceuticals's change in estimate, amount.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude